Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Solution for Injection 1 x 20 mg/ml |
|
40912 | 22363 |
Related information
Indications
Treatment of relapsed or refractory peripheral T cell lymphoma (PTCL).
Contra-Indications
None.
Special Precautions
Patients should be instructed to receive folic acid and receive B12. Caution advised in moderate to severe renal impairment. Monitor patients for liver function. May suppress bone marrow function, cause mucositis, severe dermatological reactions, tumor lysis syndrome, liver toxicity. No experience in pediatric use.
See prescribing information for full details.
Side Effects
Most common: mucositis, thrombocytopenia, nausea, and fatigue.
See prescribing information for full details.
Drug interactions
Co-administration of increasing doses of probenecid resulted in delayed clearance of pralatrexate and a commensurate increase in exposure. When administering Difolta to patients receiving probenecid or other drugs that may affect relevant transporter systems (e.g., NSAIDs), monitor patients closely for signs of systemic toxicity due to increased drug exposure.
Pregnancy and Lactation
Pregnancy: Pregnancy category D.
Lactation: Not advised during nursing.
